Calliditas Therapeutics IPO Presentation Deck
Calliditas' global commercialization
Commercial strategy
European partner
Market positioning
Market opportunity
Independent U.S. commercialization / Partner ex-US
strategy
Target IgAN patients at risk of progressing to
ESRD (up to 50%)
Earlier-stage treatment to prevent progression
and preserve kidney function
Chronic / intermittent dosing
Commercial Partner, existing
distribution channels and / or
complementary products
Targeting of therapeutically focused
nephrologists
Collaborate with patient organizations
Asia ex-Greater
China & Singapore
- Third party (IQVIA) research commissioned by the Company
2
Third party (IQVIA) research estimates applied to target population (50%) assuming bi-annual treatment
calliditas
Partner with leading organizations in each
market ex-US
Education of payors regarding
disease and severe side effects of
existing off-label treatments
Specialist target market
Potentially first approved on-label medication for IgAN, with disease modifying potential. Establish
new standard of care for IgAN
Orphan drug
U.S. market opportunity of $9-10 billion; Europe & China other significant markets near term
Up to 50% of diagnosed patients represent core target market
Additional partnerships possible - significant unmet medical need
June 2020
21View entire presentation